Mdxhealth disclosed it has received a Nasdaq noncompliance notice after failing to meet the exchange’s minimum $1.00 bid-price requirement. The company said it has fallen below the threshold for 30 consecutive business days and has 180 calendar days to regain compliance, including the need for at least a 10-consecutive-business-days closing bid at or above $1.00. Mdxhealth noted it may consider a reverse stock split if needed. The notice adds pressure at a time when Mdxhealth earlier this year discontinued a flagship urinary tract infection test and its laboratory operations in Plano, Texas, highlighting ongoing commercialization and execution challenges.